Beverly Hills Private Wealth LLC Raises Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Beverly Hills Private Wealth LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 144.3% during the 2nd quarter, Holdings Channel reports. The fund owned 4,884 shares of the medical research company’s stock after buying an additional 2,885 shares during the quarter. Beverly Hills Private Wealth LLC’s holdings in Charles River Laboratories International were worth $1,010,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of CRL. Cetera Investment Advisers grew its stake in shares of Charles River Laboratories International by 55.2% in the 2nd quarter. Cetera Investment Advisers now owns 2,792 shares of the medical research company’s stock valued at $587,000 after buying an additional 993 shares during the period. Dimensional Fund Advisors LP increased its stake in Charles River Laboratories International by 9.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 385,126 shares of the medical research company’s stock worth $80,973,000 after buying an additional 31,705 shares during the period. Banque Cantonale Vaudoise grew its stake in shares of Charles River Laboratories International by 7.4% in the second quarter. Banque Cantonale Vaudoise now owns 2,755 shares of the medical research company’s stock worth $579,000 after acquiring an additional 191 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Charles River Laboratories International by 3.5% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,926 shares of the medical research company’s stock worth $1,877,000 after acquiring an additional 301 shares during the period. Finally, Iridian Asset Management LLC CT raised its stake in shares of Charles River Laboratories International by 2.0% in the second quarter. Iridian Asset Management LLC CT now owns 67,378 shares of the medical research company’s stock valued at $14,166,000 after acquiring an additional 1,309 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $178.37 on Wednesday. The company’s 50 day simple moving average is $189.39 and its 200-day simple moving average is $198.31. The firm has a market cap of $9.15 billion, a PE ratio of 19.30, a price-to-earnings-growth ratio of 1.81 and a beta of 1.35. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $262.00. The company has a current ratio of 1.45, a quick ratio of 1.16 and a debt-to-equity ratio of 0.76.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 8th. The medical research company reported $2.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.35 by $0.37. Charles River Laboratories International had a net margin of 11.27% and a return on equity of 18.15%. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the firm posted $2.63 EPS. Charles River Laboratories International’s revenue for the quarter was up 3.8% on a year-over-year basis. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 10.56 EPS for the current year.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman acquired 1,000 shares of the firm’s stock in a transaction on Thursday, August 24th. The stock was bought at an average cost of $198.79 per share, with a total value of $198,790.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at $198,790. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have weighed in on CRL. StockNews.com began coverage on Charles River Laboratories International in a report on Thursday, October 5th. They set a “hold” rating on the stock. TD Cowen decreased their price target on shares of Charles River Laboratories International from $212.00 to $209.00 and set a “market perform” rating for the company in a research note on Monday, September 25th. Evercore ISI decreased their price objective on shares of Charles River Laboratories International from $235.00 to $225.00 in a research report on Wednesday, October 11th. JPMorgan Chase & Co. raised their price target on Charles River Laboratories International from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. Finally, UBS Group dropped their price objective on Charles River Laboratories International from $250.00 to $215.00 and set a “buy” rating on the stock in a report on Thursday, November 9th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $232.54.

About Charles River Laboratories International

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).